

- **Principle** – record the Committee meeting attendance, running, discussions
- **Links to include** – none
- **Attachments to include** – none
- **Info to include** – guideline title; meeting date/location; status of minutes (draft/confirmed); attendees; observers; apologies; agenda items and related discussions; declarations of interest; date of next meeting

Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 15

Date: 26/03/2025

Location: Virtual (Zoom)

Minutes: Final

Committee members present:

Maragret Lally (Chair)	(Present for notes 1 – 6)
Nicola Peel (Topic adviser)	(Present for notes 1 – 6)
Alison Ahmed	(Present for notes 1 – 6)
Irene Baker	(Present for notes 1 – 6)
Sherwin Criseno	(Present for notes 1 – 6)
Elaine Dennison	(Present for notes 1 – 6)
Paul Hamilton	(Present for notes 1 – 6)
Karen Knapp	(Present for notes 1 – 6)
Iain Macleod	(Present for notes 1 – 6)
Kay Morgan	(Present for notes 1 – 6)
Rachel Muir	(Present for notes 1 – 6)
Nicholas Pipkin	(Present for notes 1 – 6)
Stuart Ralston	(Present for notes 1 – 6)
Rajesh Varma	(Present for notes 1 – 6)
Karen Whitehead	(Present for notes 1 – 6)

In attendance:

Rebecca Boucher	Content Designer	(Present for notes 1 – 6)
Annette Chalker	Technical Analyst	(Present for notes 1 – 6)
Linyun Fun	Technical Analyst	(Present for notes 1 – 6)
Amber Hernaman	Project Manager	(Present for notes 1 – 6)

4.0.03 DOC Cmte minutes

Clare Jones	Senior Technical Analyst	(Present for notes 1 – 6)
Qudsia Malik	Senior Technical Analyst	(Present for notes 1 – 6)
Lisa Miles	Technical Analyst	(Present for notes 1 – 6)
Suzie Panek	Resource Impact	(Present for notes 1 – 6)
Muksitur Rahman	Health Economist	(Present for notes 1 – 6)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 6)

Apologies:

Sarah Glover	Information specialist
Lisa Miles	Technical analyst

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 15th Osteoporosis guideline committee.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- Revisiting the recommendations on follow up/monitoring for people not on treatment (6.1) and treatment pauses (7.3)
- BMD assessment and treatment initiation criteria and analysis

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was on follow up/monitoring for people not on treatment and treatment pauses.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting.

Name	Affiliation	Declarations of Interest, date declared	Type of interest	Decision taken
Elaine Dennison	Committee member	Speaker on non-promotional educational lectures commissioned by the International Osteoporosis Foundation (rare adverse effects of bisphosphonate treatment; HRT and Selective Estrogen Receptor Modulators)	Direct financial	Declare and participate.
Elaine	Committee	Editor for non-promotional book on	Direct	Declare

4.0.03 DOC Cmte minutes

Dennison	member	osteoporosis, produced by Karger	financial	and participate.
Karen Knapp	Committee member	DXA reporting radiographer for InHealth	Direct financial	Declare and participate.
Karen Knapp	Committee member	DXA reporting Radiographer for Dorset County Hospital	Direct financial	Declare and participate.
Karen Knapp	Committee member	<p>Partial funding to attend European Congress of Radiology as an invited speaker. Sessions:</p> <p>We've travelled the road before: ask me anything about my successful research career (moderator)</p> <p>Promoting compassionate care education and training in radiography (invited presentation)</p> <p>Effective writing and publishing in Radiography (invited presentation)</p> <p>Advancing radiography: impact, innovation and integrated healthcare (moderator)</p>	Direct financial	Declare and participate.
<p>The Chair and a senior member of the Developer's team noted that the following member would not participate in a part of the meeting: Karen Knapp, was excluded from the DXA portion of recommendation drafting on follow up/monitoring for people not on treatment at 10:25.</p>				
3. Minutes of last meeting				
Agreed as an accurate record.				
4. Recommendations				
<p>Carlos Sharpin presented and made live edits to the recommendations on follow up/monitoring for people not on treatment.</p> <p>Qudsia Malik presented the summary of evidence for the review on treatment pauses and Carlos Sharpin made edits to the recommendations.</p>				
5. Health economics				
Kate Lovibond presented the BMD assessment and treatment initiation criteria				

4.0.03 DOC Cmte minutes

analysis.
6. AOB
None.

Date of next meeting: 28/04/2025

Location of next meeting: Zoom